Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism

Anesthesia and Analgesia

Volumn 106, Issue 4, 2008, Pages 1101-1103

  Bauer, Christian ^a,b   Vichova, Zuzana ^a,b   Ffrench, Patrick ^a,b   Hercule, Christiane ^a   Jegaden, Olivier ^a,b   Bastien, Olivier ^a,b   Lehot, Jean Jacques ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; HEPARIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 41349094421     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31816794d9     Document Type: Article

References (29)

1. Hsieh PC, Wang SS, Ko WJ, Han YY, Chu SH. Successful resuscitation of acute massive pulmonary embolism with extracorporeal membrane oxygenation and open embolectomy. Ann Thorac Surg 2001;72:266-7
2. Davies MJ, Arsiwala SS, Moore HM, Kerr S, Sosnowski AW, Firmin RK. Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism. Ann Thorac Surg 1995;60:1801-3
3. Misawa Y, Fuse K, Yamaguchi T, Saito T, Konishi H. Mechanical circulatory assist for pulmonary embolism. Perfusion 2000;15:527-9
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:311S-337S
5. Grocott HP, Root J, Berkowitz SD, deBruijn N, Landolfo K. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. J Cardiothorac Vasc Anesth 1997;11:875-7
6. Insler SR, Kraenzler EJ, Bartholomew JR, Kottke-Marchant K, Lytle B, Starr NJ. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthesiology 1997;86:495-8
7. Gillis S, Merin G, Zahger D, Deeb M, Drenger B, Hyam E, Eldor A. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997;98:657-9
8. Salmi L, Elalamy I, Leroy-Matheron C, Houel R, Thebert D, Duvaldestin P. Thrombosis of a cardiopulmonary bypass circuit despite recommended hypocoagulation with danaparoid during the acute phase of type II heparin-induced thrombocytopenia. Ann Fr Anesth Reanim 2006;25:1144-8
9. Ariano RE, Bhattacharya SK, Moon M, Brownell LG. Failure of danaparoid anticoagulation for cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000;119:167-8
10. Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, Van Trigt P III. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990;73:562-5
11. Olin DA, Urdaneta F, Lobato EB. Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2000;14:707-9
12. Aouifi A, Blanc P, Piriou V, Bastien OH, Ffrench P, Hanss M, Lehot JJ. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001;71:678-83
13. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006;95:967-81
14. Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996;61:920-4
15. Christiansen S, Geiger A, Splittgerber FH, Reidemeister JC. Aortocoronary vein bypass in a patient with type II heparin-associated thrombopenia: a case report. Int J Angiol 1998;7:268-70
16. Pineau E, Le Bret E, Folliguet T, Saint Maurice OS, Carbognani D, Laborde F. Use of Organon, a synthetic heparinoid, in two cardiopulmonary bypass procedures in the same patient sensitive to heparin. Arch Mal Coeur Vaiss 2001;94:144-7
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703
18. Ferrari E, Chevallier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999;115:440-4
19. Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. J Clin Anesth 2000;12:324-7
20. Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 2001;114:394-6
21. Gitlin SD, Deeb GM, Yann C, Schmaier AH. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 1998;27:568-75
22. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005;127:1S-8S
23. Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 2nd ed. New York: Marcel Dekker, 2001:429-44
24. Nowak G, Bucha E, Goock T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992;66:707-15
25. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000;14:243-8
26. Lehot JJ, Gostoli B, Ffrench P, Berruyer M, Hanss M. Treatment by lepirudin and acenocoumarol of heparin induced thrombocytopenia after valvular surgery: a word of caution. Ann Fr Anesth Reanim 2006;25:1140-3
27. Koster A, Sanger S, Hansen R, Sodian R, Mertzlufft F, Harke C, Kuppe H, Hetzer R, Loebe M. Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. ASAIO J 2000;46:319-22
28. Peek GJ, Moore HM, Moore N, Sosnowski AW, Firmin RK. Extracorporeal membrane oxygenation for adult respiratory failure. Chest 1997;112:759-64
29. Cheung PY, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med 2000;28:2584-90